Le Lézard
Classified in: Health
Subject: OBI

Endoceutics Mourns the Death of Dr. Fernand Labrie


QUEBEC CITY, Jan. 17, 2019 /CNW Telbec/ - It is with great sadness that Endoceutics management announces the death of its president and founder Dr. Fernand Labrie at the age of 81.

Logo: Endoceutics (CNW Group/Endoceutics)

Dr. Labrie, a graduate of the Faculty of Medicine of Université Laval, also studied at the University of Cambridge in the U.K. He dedicated the bulk of his career to studying the mechanism of hormone action. He founded the Laboratory of Molecular Endocrinology at Université Laval, which he directed for 40 years. His research led to important discoveries in the treatment of prostate cancer. Over the course of his prolific career, Dr. Labrie headed the CHUL (Centre hospitalier de l'Université Laval) Research Centre and published over 1,200 scientific articles. More recently, he had turned his attention to women's health issues. In 2006 he founded Endoceutics, which today develops and commercializes treatments for the symptoms of menopause.

Dr. Labrie received numerous awards and distinctions over the course of his career, including the Prince of Wales Award, the Medal of the Governor General of Canada, Officer of the Order of Canada, the Queen's Diamond Jubilee Medal, and Professor Emeritus of Université Laval.

Endoceutics is very proud of Dr. Labrie's many accomplishments and intends to pursue his work and mission.

Dr. Labrie's family wishes to mourn in private and will not be granting interviews.

 

SOURCE Endoceutics


These press releases may also interest you

at 22:03
Health & Wellness Food Market Projected to Reach $859.43 billion by 2030 - Exclusive Report by 360iResearch
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

at 21:27
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...

at 19:30
Astellas' XTANDItm (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Astellas Pharma Inc....

at 19:15
New Study in Colorado Reveals Alarming Rates of Colorado Teens Missing School
Denver nonprofit Justice Necessary unveils data from its latest study on teen period poverty in Colorado, shedding light on a deeply concerning issue. The findings of this study underscore the urgent need for action to address the need for teens to...

at 19:05
Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched...

at 18:00
Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plustm, the First Prescription Digital Therapeutic Authorized for the Treatment of Postpartum Depression (PPD)
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...

More news about Health...


News published on and distributed by: